Cargando…
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
Seasonal influenza infections have a significant global impact leading to increased health and economic burden. The efficacy of currently available seasonal influenza vaccines targeting polymorphic surface antigens has historically been suboptimal. Cellular immune responses against highly conserved...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466103/ https://www.ncbi.nlm.nih.gov/pubmed/30909516 http://dx.doi.org/10.3390/vaccines7010033 |
_version_ | 1783411033098944512 |
---|---|
author | Folegatti, Pedro M. Bellamy, Duncan Flaxman, Amy Mair, Catherine Ellis, Chris L. Ramon, Raquel Ramos Lopez, Fernando Mitton, Celia Baker, Megan Poulton, Ian Lawrie, Alison Roberts, Rachel Minassian, Angela Ewer, Katie J. Evans, Thomas G. Hill, Adrian V. S. Gilbert, Sarah C. |
author_facet | Folegatti, Pedro M. Bellamy, Duncan Flaxman, Amy Mair, Catherine Ellis, Chris L. Ramon, Raquel Ramos Lopez, Fernando Mitton, Celia Baker, Megan Poulton, Ian Lawrie, Alison Roberts, Rachel Minassian, Angela Ewer, Katie J. Evans, Thomas G. Hill, Adrian V. S. Gilbert, Sarah C. |
author_sort | Folegatti, Pedro M. |
collection | PubMed |
description | Seasonal influenza infections have a significant global impact leading to increased health and economic burden. The efficacy of currently available seasonal influenza vaccines targeting polymorphic surface antigens has historically been suboptimal. Cellular immune responses against highly conserved Influenza A virus antigens, such as nucleoprotein (NP) and matrix protein-1 (M1), have previously been shown to be associated with protection from disease, whilst viral-vectored vaccines are an effective strategy to boost cell-mediated immunity. We have previously demonstrated that MVA encoding NP and M1 can induce potent and persistent T cell responses against influenza. In this Phase I study, we evaluated the safety and immunogenicity of MVA-NP+M1, which was newly manufactured on an immortalized cell line, in six healthy adult participants. The vaccine was well-tolerated with only mild to moderate adverse events that resolved spontaneously and were comparable to previous studies with the same vaccine manufactured in chick embryo fibroblasts. A significant increase in vaccine-specific T cell responses was detected seven days after immunization and was directed against both antigens in the vector insert. This small Phase I study supports progression of this vaccine to a Phase IIb study to assess immunogenicity and additional protective efficacy in older adults receiving licensed seasonal influenza vaccines. |
format | Online Article Text |
id | pubmed-6466103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64661032019-04-18 Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line Folegatti, Pedro M. Bellamy, Duncan Flaxman, Amy Mair, Catherine Ellis, Chris L. Ramon, Raquel Ramos Lopez, Fernando Mitton, Celia Baker, Megan Poulton, Ian Lawrie, Alison Roberts, Rachel Minassian, Angela Ewer, Katie J. Evans, Thomas G. Hill, Adrian V. S. Gilbert, Sarah C. Vaccines (Basel) Article Seasonal influenza infections have a significant global impact leading to increased health and economic burden. The efficacy of currently available seasonal influenza vaccines targeting polymorphic surface antigens has historically been suboptimal. Cellular immune responses against highly conserved Influenza A virus antigens, such as nucleoprotein (NP) and matrix protein-1 (M1), have previously been shown to be associated with protection from disease, whilst viral-vectored vaccines are an effective strategy to boost cell-mediated immunity. We have previously demonstrated that MVA encoding NP and M1 can induce potent and persistent T cell responses against influenza. In this Phase I study, we evaluated the safety and immunogenicity of MVA-NP+M1, which was newly manufactured on an immortalized cell line, in six healthy adult participants. The vaccine was well-tolerated with only mild to moderate adverse events that resolved spontaneously and were comparable to previous studies with the same vaccine manufactured in chick embryo fibroblasts. A significant increase in vaccine-specific T cell responses was detected seven days after immunization and was directed against both antigens in the vector insert. This small Phase I study supports progression of this vaccine to a Phase IIb study to assess immunogenicity and additional protective efficacy in older adults receiving licensed seasonal influenza vaccines. MDPI 2019-03-22 /pmc/articles/PMC6466103/ /pubmed/30909516 http://dx.doi.org/10.3390/vaccines7010033 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Folegatti, Pedro M. Bellamy, Duncan Flaxman, Amy Mair, Catherine Ellis, Chris L. Ramon, Raquel Ramos Lopez, Fernando Mitton, Celia Baker, Megan Poulton, Ian Lawrie, Alison Roberts, Rachel Minassian, Angela Ewer, Katie J. Evans, Thomas G. Hill, Adrian V. S. Gilbert, Sarah C. Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line |
title | Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line |
title_full | Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line |
title_fullStr | Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line |
title_full_unstemmed | Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line |
title_short | Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line |
title_sort | safety and immunogenicity of the heterosubtypic influenza a vaccine mva-np+m1 manufactured on the age1.cr.pix avian cell line |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466103/ https://www.ncbi.nlm.nih.gov/pubmed/30909516 http://dx.doi.org/10.3390/vaccines7010033 |
work_keys_str_mv | AT folegattipedrom safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT bellamyduncan safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT flaxmanamy safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT maircatherine safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT ellischris safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT lramonraquel safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT ramoslopezfernando safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT mittoncelia safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT bakermegan safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT poultonian safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT lawriealison safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT robertsrachel safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT minassianangela safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT ewerkatiej safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT evansthomasg safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT hilladrianvs safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline AT gilbertsarahc safetyandimmunogenicityoftheheterosubtypicinfluenzaavaccinemvanpm1manufacturedontheage1crpixaviancellline |